Products for Out-Licensing

Partner with Aptalis Pharmaceutical Technologies to expand your product portfolio.

Aptalis Pharmaceutical Technologies has a portfolio of Rx and OTC products available for licensing that utilize our drug delivery technologies to create new formulations for products with proven patient benefits.

We license a portfolio of products to pharmaceutical companies for marketing throughout the world. Several of those available for out-licensing are detailed below.

Click here to contact Aptalis Pharmaceutical Technologies for more information about licensing opportunities.

Therapeutic Category	Product Name	Development Status	Aptalis Pharmaceutical Technologies Technology
Cardiovascular	Diltiazem (once daily) Extended-Release Capsules	Commercialized; Licensing opportunities available	Diffucaps®
	Nifedipine (once daily) Extended-Release Capsules	Commercialized; Licensing opportunities available	Eurand Minitabs®
Sleep Aid	AdvaTab® Temazepam Orally Disintegrating Tablets	Formulated (Multiple doses)	AdvaTab®
	AdvaTab® Diphenhydramine HCl Orally Disintegrating Tablets	Commercialized; Licensing opportunities available	Microcaps® AdvaTab®
Gastroenterology	Paraffin Oil + Psyllium	Commercialized; Licensing opportunities available	Microcaps®
Nutrition	Vitamin C (once daily) Extended-Release Capsules Vitamin C / Zinc – Combination Food Product	Commercialized; Licensing opportunities available	Diffucaps®
Pain	Cyclobenzaprine HCl (once daily) Extended-Release Capsules	Commercialized; Licensing opportunities available	Diffucaps®
	AdvaTab® Paracetamol (acetaminophen) Orally Disintegrating Tablets	USP Monograph OTC: Ready to launch	Microcaps® AdvaTab®
	Diclofenac Sodium Extended-Release Capsules	Commercialized; Licensing opportunities available	Diffucaps®

 

This information is provided solely for the purpose of the evaluation of business opportunities by potential collaboration partners. The information is based on currently existing data and marketing authorizations in a number of jurisdictions and should not be assumed to be approved by regulatory authorities in any individual country. Consumers should consult with their individual physician for product information and should not rely upon any information provided here.

For more information on these products, please contact Aptalis Pharmaceutical Technologies.